Skip to content

Comparison of dexmedetomidine and propofol combined with fentanyl for IDDS implantation in patients with advanced cancer pain

Comparison of dexmedetomidine and propofol combined with fentanyl for IDDS implantation in patients with advanced cancer pain

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025079
Enrollment
Unknown
Registered
2019-08-10
Start date
2019-08-09
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IDDS implantation for advanced cancer pain patients

Interventions

dexmedetomidine combined with fentanyl group:Fentanyl was injected 1 µg/kg 5min before surgery,patients were intravenously pumped with dexmedetomidine 0.5 µg/kg within 10min prior to surgery and conti
Propofol combined with fentanyl group:Fentanyl was injected 1 µg/kg 5min before surgery,within 10min before the operation, the patient was intravenously pumped with 2mg/kg propofol. After the operatio
Fentanyl group:Fentanyl was injected 1 µg/kg 5min before surgery

Sponsors

Jiangsu Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Aged 18 years or more, ASA II or III level. Patients with primary abdominal tumors with poor analgesic effect of oral opioids (mesecontin >=300 mg/d, VAS resting >= 5 and >3 times/day) or who cannot tolerate side effects of large doses of opioids.

Exclusion criteria

Exclusion criteria: Serious heart and lung disease, severe bradycardia, poor control of high blood pressure, unstable angina, II degree atrioventricular block, subarachnoid puncture taboo, to right the microphones, fat emulsion and other allergies, can not tolerate surgery or unfinished, unwilling to cooperate with researchers and so on.

Design outcomes

Primary

MeasureTime frame
VAS;Ramsay;

Countries

China

Contacts

Public ContactSun Xiaodi

The First Affiliated Hospital of Nanjing Medical University

sun321victor@163.com+86 15050588681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026